These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 39287805)

  • 21. Distinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomas.
    Godfraind C; Kaczmarska JM; Kocak M; Dalton J; Wright KD; Sanford RA; Boop FA; Gajjar A; Merchant TE; Ellison DW
    Acta Neuropathol; 2012 Aug; 124(2):247-57. PubMed ID: 22526017
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MRI Phenotype of RELA-fused Pediatric Supratentorial Ependymoma.
    Nowak J; Jünger ST; Huflage H; Seidel C; Hohm A; Vandergrift LA; von Hoff K; Rutkowski S; Pietsch T; Warmuth-Metz M
    Clin Neuroradiol; 2019 Dec; 29(4):595-604. PubMed ID: 30027327
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular grouping and outcomes of young children with newly diagnosed ependymoma treated on the multi-institutional SJYC07 trial.
    Upadhyaya SA; Robinson GW; Onar-Thomas A; Orr BA; Billups CA; Bowers DC; Bendel AE; Hassall T; Crawford JR; Partap S; Fisher PG; Tatevossian RG; Seah T; Qaddoumi IA; Vinitsky A; Armstrong GT; Sabin ND; Tinkle CL; Klimo P; Indelicato DJ; Boop FA; Merchant TE; Ellison DW; Gajjar A
    Neuro Oncol; 2019 Oct; 21(10):1319-1330. PubMed ID: 30976811
    [TBL] [Abstract][Full Text] [Related]  

  • 24. L1CAM Immunopositivity in Anaplastic Supratentorial Ependymomas: Correlation With Clinical and Histological Parameters.
    Chavali P; Rao S; Palavalasa S; Bevinahalli N; Muthane YTC; Sadashiva N; Santosh V
    Int J Surg Pathol; 2019 May; 27(3):251-258. PubMed ID: 30251576
    [TBL] [Abstract][Full Text] [Related]  

  • 25. EZHIP: a new piece of the puzzle towards understanding pediatric posterior fossa ependymoma.
    Jenseit A; Camgöz A; Pfister SM; Kool M
    Acta Neuropathol; 2022 Jan; 143(1):1-13. PubMed ID: 34762160
    [TBL] [Abstract][Full Text] [Related]  

  • 26. C11orf95-RELA fusions and upregulated NF-KB signalling characterise a subset of aggressive supratentorial ependymomas that express L1CAM and nestin.
    Malgulwar PB; Nambirajan A; Pathak P; Faruq M; Rajeshwari M; Singh M; Suri V; Sarkar C; Sharma MC
    J Neurooncol; 2018 May; 138(1):29-39. PubMed ID: 29354850
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Distinct relapse pattern across molecular ependymoma types.
    Obrecht-Sturm D; Schoof M; Eckhardt A; Mynarek M; Gilbert MR; Aldape K; Armstrong TS; Ramaswamy V; Bockmayr M; von Hoff K; Fleischhack G; Adolph JE; Tippelt S; Pfister SM; Pajtler K; Sturm D; Drexler R; Ricklefs FL; Stepien N; Gojo J; Pietsch T; Warmuth-Metz M; Kortmann R; Timmermann B; Haberler C; Rutkowski S; Schüller U
    Neuro Oncol; 2024 Aug; ():. PubMed ID: 39171767
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ependymoma: Evaluation and Management Updates.
    Rudà R; Bruno F; Pellerino A; Soffietti R
    Curr Oncol Rep; 2022 Aug; 24(8):985-993. PubMed ID: 35384591
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Supra-tentorial Ependymomas with ZFTA Fusion, YAP1 Fusion, and Astroblastomas, MN1-altered: Characteristic Imaging Features.
    Perrod V; Levy R; Tauziède-Espariat A; Roux CJ; Beccaria K; Blauwblomme T; Grill J; Dufour C; Guerrini-Rousseau L; Abbou S; Bolle S; Roux A; Pallud J; Provost C; Oppenheim C; Varlet P; Boddaert N; Dangouloff-Ros V
    Clin Neuroradiol; 2024 Aug; ():. PubMed ID: 39093426
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy.
    Witt DA; Donson AM; Amani V; Moreira DC; Sanford B; Hoffman LM; Handler MH; Levy JMM; Jones KL; Nellan A; Foreman NK; Griesinger AM
    Pediatr Blood Cancer; 2018 May; 65(5):e26960. PubMed ID: 29350470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular characteristics and improved survival prediction in a cohort of 2023 ependymomas.
    Pohl LC; Leitheiser M; Obrecht D; Schweizer L; Wefers AK; Eckhardt A; Raffeld M; Sturm D; Pajtler KW; Rutkowski S; Fukuoka K; Ichimura K; Bockmayr M; Schüller U
    Acta Neuropathol; 2024 Jan; 147(1):24. PubMed ID: 38265522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A coordinated approach for the assessment of molecular subgroups in pediatric ependymomas using low-cost methods.
    de Sousa GR; Lira RCP; de Almeida Magalhães T; da Silva KR; Nagano LFP; Saggioro FP; Baroni M; Marie SKN; Oba-Shinjo SM; Brandelise S; de Paula Queiroz RG; Brassesco MS; Scrideli CA; Tone LG; Valera ET
    J Mol Med (Berl); 2021 Aug; 99(8):1101-1113. PubMed ID: 33903940
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Supratentorial ependymoma in childhood: more than just RELA or YAP.
    Zschernack V; Jünger ST; Mynarek M; Rutkowski S; Garre ML; Ebinger M; Neu M; Faber J; Erdlenbruch B; Claviez A; Bielack S; Brozou T; Frühwald MC; Dörner E; Dreschmann V; Stock A; Solymosi L; Hench J; Frank S; Vokuhl C; Waha A; Andreiuolo F; Pietsch T
    Acta Neuropathol; 2021 Mar; 141(3):455-466. PubMed ID: 33481105
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular subtyping of ependymoma and prognostic impact of Ki-67.
    Lim KY; Lee K; Shim Y; Park JW; Kim H; Kang J; Won JK; Kim SK; Phi JH; Park CK; Chung CK; Yun H; Park SH
    Brain Tumor Pathol; 2022 Jan; 39(1):1-13. PubMed ID: 34812989
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ependymoma-like tumor with mesenchymal differentiation (ELTMD) with ZFTA:NCOA1 fusion: A diagnostic challenge.
    Dorwal P; White C; Goh AF; Kumar A; McEniery J; Walker R; Robertson T
    Neuropathology; 2024 Jun; 44(3):216-221. PubMed ID: 37931917
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Updates in the classification of ependymal neoplasms: The 2021 WHO Classification and beyond.
    Kresbach C; Neyazi S; Schüller U
    Brain Pathol; 2022 Jul; 32(4):e13068. PubMed ID: 35307892
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostics of pediatric supratentorial RELA ependymomas: integration of information from histopathology, genetics, DNA methylation and imaging.
    Pagès M; Pajtler KW; Puget S; Castel D; Boddaert N; Tauziède-Espariat A; Picot S; Debily MA; Kool M; Capper D; Sainte-Rose C; Chrétien F; Pfister SM; Pietsch T; Grill J; Varlet P; Andreiuolo F
    Brain Pathol; 2019 May; 29(3):325-335. PubMed ID: 30325077
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic and microRNA profile analysis for CD44 positive expression pediatric posterior fossa ependymoma.
    Shu C; Wang Q; Yan X; Wang J
    Clin Transl Oncol; 2018 Nov; 20(11):1439-1447. PubMed ID: 29704232
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment implications of posterior fossa ependymoma subgroups.
    Ramaswamy V; Taylor MD
    Chin J Cancer; 2016 Nov; 35(1):93. PubMed ID: 27846874
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Supra- and infratentorial pediatric ependymomas differ significantly in NeuN, p75 and GFAP expression.
    Hagel C; Treszl A; Fehlert J; Harder J; von Haxthausen F; Kern M; von Bueren AO; Kordes U
    J Neurooncol; 2013 Apr; 112(2):191-7. PubMed ID: 23371454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.